Search details
1.
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.
Lancet Oncol
; 24(9): 1002-1017, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37657460
2.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Article
in English
| MEDLINE | ID: mdl-32997907
3.
Overweight and obesity in polycystic ovary syndrome: association with inflammation, oxidative stress and dyslipidaemia.
Br J Nutr
; 128(4): 604-612, 2022 08 28.
Article
in English
| MEDLINE | ID: mdl-34511137
4.
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2.
Future Oncol
; 18(33): 3701-3711, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-36135712
5.
Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial.
J Thorac Oncol
; 19(2): 297-313, 2024 02.
Article
in English
| MEDLINE | ID: mdl-37748693
6.
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer.
J Clin Oncol
; : JCO2302110, 2024 Apr 22.
Article
in English
| MEDLINE | ID: mdl-38648575
7.
Avelumab in Combination With Cetuximab and Chemotherapy as First-Line Treatment for Patients With Advanced Squamous NSCLC.
JTO Clin Res Rep
; 4(2): 100461, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36718142
8.
Lung hamartoma--diagnosis and treatment.
Med Arch
; 66(4): 281-2, 2012.
Article
in English
| MEDLINE | ID: mdl-22919888
9.
Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer: A Randomized Controlled Trial.
BioDrugs
; 36(6): 749-760, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36169807
10.
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial.
Nat Med
; 28(9): 1831-1839, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35995953
11.
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC).
BioDrugs
; 35(4): 417-428, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-34264503
12.
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Clin Lung Cancer
; 22(5): 449-460, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33895103
13.
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Curr Pharm Des
; 27(36): 3812-3820, 2021.
Article
in English
| MEDLINE | ID: mdl-33463457
14.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
J Thorac Oncol
; 16(11): 1872-1882, 2021 11.
Article
in English
| MEDLINE | ID: mdl-34265434
15.
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Adv Ther
; 38(1): 350-365, 2021 01.
Article
in English
| MEDLINE | ID: mdl-33123968
16.
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA).
BioDrugs
; 35(4): 429-444, 2021 Jul.
Article
in English
| MEDLINE | ID: mdl-33914256
17.
Hypertension in Polycystic Ovary Syndrome: Novel Insights.
Curr Hypertens Rev
; 16(1): 55-60, 2020.
Article
in English
| MEDLINE | ID: mdl-31146668
18.
Evaluation of a Summary Score for Dyslipidemia, Oxidative Stress and Inflammation (the Doi Score) in Women with Polycystic Ovary Syndrome and its Relationship with Obesity.
J Med Biochem
; 37(4): 476-485, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30584408
19.
Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Curr Pharm Des
; 24(38): 4593-4597, 2018.
Article
in English
| MEDLINE | ID: mdl-30652641
20.
Lipid accumulation product as a marker of cardiometabolic susceptibility in women with different phenotypes of polycystic ovary syndrome.
Eur J Endocrinol
; 175(6): 551-560, 2016 Dec.
Article
in English
| MEDLINE | ID: mdl-27634940